ChromaDex Co. (NASDAQ:CDXC) Sees Significant Increase in Short Interest

ChromaDex Co. (NASDAQ:CDXC) saw a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 1,320,000 shares, an increase of 12.8% from the March 15th total of 1,170,000 shares. Based on an average daily trading volume, of 259,700 shares, the short-interest ratio is currently 5.1 days. Approximately 3.0% of the shares of the company are short sold.

Analysts Set New Price Targets

Several brokerages have commented on CDXC. StockNews.com began coverage on ChromaDex in a research report on Sunday, March 3rd. They issued a “strong-buy” rating on the stock. Roth Mkm lifted their price target on ChromaDex from $4.25 to $6.00 and gave the stock a “buy” rating in a research report on Tuesday, April 9th.

Institutional Trading of ChromaDex

Institutional investors and hedge funds have recently modified their holdings of the company. Envestnet Asset Management Inc. bought a new stake in shares of ChromaDex during the second quarter valued at approximately $25,000. Bank of America Corp DE grew its position in ChromaDex by 130.4% in the first quarter. Bank of America Corp DE now owns 16,469 shares of the company’s stock valued at $25,000 after acquiring an additional 9,321 shares during the period. Squarepoint Ops LLC bought a new stake in ChromaDex in the first quarter valued at $28,000. LPL Financial LLC grew its position in ChromaDex by 52.9% in the second quarter. LPL Financial LLC now owns 28,915 shares of the company’s stock valued at $45,000 after acquiring an additional 10,000 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in ChromaDex by 74.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 39,300 shares of the company’s stock valued at $66,000 after acquiring an additional 16,800 shares during the period. 15.41% of the stock is currently owned by institutional investors.

ChromaDex Price Performance

Shares of CDXC traded up $0.01 on Tuesday, reaching $3.94. 249,892 shares of the stock traded hands, compared to its average volume of 253,730. The firm has a market cap of $296.72 million, a price-to-earnings ratio of -56.28 and a beta of 1.98. ChromaDex has a 12 month low of $1.25 and a 12 month high of $4.65. The stock’s 50-day moving average price is $2.52 and its 200-day moving average price is $1.81.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.